Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons
Xue Zou, David R. Brigstock

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2848 - 2848

Published: Dec. 14, 2024

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of triglycerides within hepatocytes, which can progress to more severe conditions, such as metabolic steatohepatitis (MASH), may include progressive fibrosis, leading cirrhosis, cancer, and death. This goal this review highlight recent research showing potential mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in reducing key pathogenic pathways MASLD or MASH. Methods: Relevant published studies were identified using PubMed with one following search terms: MASLD, MASH, NAFLD, NASH, exosome, vesicle (EV), therapy, and/or cells (MSC). The primary literature subsequently downloaded summarized. Results: Using vitro vivo models, MSC-EVs have been found counteract oxidative stress, a significant contributor injury suppress progression, including steatosis, inflammation, and, few instances, fibrosis. Some these outcomes attributed specific EV cargo components microRNAs proteins. Thus, enriched types molecules improved therapeutic efficacy for MASLD/MASH represent novel approach potentially halt reverse process. Conclusions: are attractive agents treating MASLD/MASH. Further necessary validate clinical applicability human MASH patients, focusing on optimizing delivery strategies identifying that targeted components.

Language: Английский

Emerging role of exosomes in cancer therapy: progress and challenges DOI Creative Commons
Jiale Li,

Jiachong Wang,

Zigui Chen

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 13, 2025

This review highlights recent progress in exosome-based drug delivery for cancer therapy, covering exosome biogenesis, cargo selection mechanisms, and their application across multiple types. As small extracellular vesicles, exosomes exhibit high biocompatibility low immunogenicity, making them ideal vehicles capable of efficiently targeting cells, minimizing off-target damage side effects. aims to explore the potential with a focus on applications chemotherapy, gene immunomodulation. Additionally, challenges related production standardization are analyzed, highlighting importance addressing these issues clinical application. In conclusion, systems offer promising future therapies. Further research should aim enhance efficiency facilitate translation, paving way innovative treatment strategies.

Language: Английский

Citations

10
Exosome Source Matters: A Comprehensive Review from the Perspective of Diverse Cellular Origins DOI Creative Commons
Y Chen, Weili Qi, Zhenghao Wang

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 147 - 147

Published: Jan. 22, 2025

Exosomes have emerged as promising therapeutic agents in regenerative medicine. This review introduces a novel cell type-oriented perspective to systematically analyze exosomal properties therapies. To our knowledge, this is the first comprehensively compare exosomes based on cellular source type, offering unprecedented insights into selecting optimal exosome producers for targeted applications. Factors beyond origin influencing efficacy, such donor sites and collection methods, are also explored here. By synthesizing key advances, we propose research directions end. We aim accelerate development of more effective exosome-based therapies highlight underexplored rapidly evolving field.

Language: Английский

Citations

0
Recent Progress in Developing Extracellular Vesicles as Nanovehicles to Deliver Carbohydrate-Based Therapeutics and Vaccines DOI Creative Commons

Japigorn Puagsopa,

Niksa Tongviseskul,

Thapakorn Jaroentomeechai

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 285 - 285

Published: March 7, 2025

Cell-derived, nanoscale extracellular vesicles (EVs) have emerged as promising tools in diagnostic, therapeutic, and vaccine applications. Their unique properties including the capability to encapsulate diverse molecular cargo well versatility surface functionalization make them ideal candidates for safe effective vehicles deliver a range of biomolecules gene editing cassettes, therapeutic proteins, glycans, glycoconjugate vaccines. In this review, we discuss recent advances development EVs derived from mammalian bacterial cells use delivery carbohydrate-based protein therapeutics We highlight key innovations EVs’ design, characterization, deployment treating diseases Alzheimer’s disease, infectious diseases, cancers. challenges their clinical translation provide perspectives future within biopharmaceutical research landscape.

Language: Английский

Citations

0
Exosomes as Biomarkers and Therapeutic Agents in Neurodegenerative Diseases: Current Insights and Future Directions DOI Creative Commons

Sam Dehghani,

Ozgecan Ocakcı,

Pars Tan Hatipoglu

et al.

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 17, 2025

Abstract Neurodegenerative diseases (NDs) like Alzheimer’s, Parkinson’s, and ALS rank among the most challenging global health issues, marked by substantial obstacles in early diagnosis effective treatment. Current diagnostic techniques frequently demonstrate inadequate sensitivity specificity, whilst conventional treatment strategies encounter challenges related to restricted bioavailability insufficient blood–brain barrier (BBB) permeability. Recently, exosomes—nanoscale vesicles packed with proteins, RNAs, lipids—have emerged as promising agents potential reshape therapeutic approaches these diseases. Unlike drug carriers, they naturally traverse BBB can deliver bioactive molecules affected neural cells. Their molecular cargo influence cell signaling, reduce neuroinflammation, potentially slow neurodegenerative progression. Moreover, exosomes serve non-invasive biomarkers, enabling precise while allowing real-time disease monitoring. Additionally, engineered exosomes, loaded molecules, enhance this capability targeting diseased neurons overcoming barriers. By offering enhanced reduced immunogenicity, an ability bypass physiological limitations, exosome-based present a transformative advantage over existing approaches. This review examines multifaceted role of NDDs, emphasizing their capabilities, intrinsic functions, advanced vehicles.

Language: Английский

Citations

0
Delivering RNA through exosomes for cancer therapy DOI
Tianming Zhao, Jinping Wang

Journal of Nanoparticle Research, Journal Year: 2025, Volume and Issue: 27(4)

Published: March 20, 2025

Language: Английский

Citations

0
EMERGING ROLE OF EXOSOMAL microRNA IN OBESITY DOI

Achala Theres P. Moncy,

Samarjit Das, Hannah R. Vasanthi

et al.

Current Opinion in Physiology, Journal Year: 2025, Volume and Issue: unknown, P. 100827 - 100827

Published: April 1, 2025

Language: Английский

Citations

0
Exosome-based nanomedicines for digestive system tumors therapy DOI

Ge Song,

Chenlu Zeng, Junru Li

et al.

Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 14

Published: April 18, 2025

Digestive system tumors constitute a major subset of malignancies, consistently ranking among the leading causes mortality globally. Despite limitations inherent in current therapeutic modalities, recent advancements targeted therapy and drug delivery systems have led to significant improvements efficacy pharmacotherapy for digestive tumors. In this context, exosomes - naturally occurring nanoscale vesicles emerged as promising candidates due their intrinsic molecular transport capabilities, superior biocompatibility, recognition tumor cells. The integration into cancer therapeutics represents novel potentially transformative approach treating tumors, which may drive further progress field. This review comprehensively examines sources, loading mechanisms, context treatment. Furthermore, it discusses opportunities challenges associated with exosomes, offering insights future role within armamentarium against

Language: Английский

Citations

0
Therapeutic combinations of exosomes alongside cancer stem cells (CSCs) and of CSC-derived exosomes (CSCEXs) in cancer therapy DOI Creative Commons

Arefeh Zabeti Touchaei,

Seyedeh Elham Norollahi,

Ali Najafizadeh

et al.

Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)

Published: Oct. 5, 2024

Language: Английский

Citations

2
miRNA-124 loaded extracellular vesicles encapsulated within hydrogel matrices for combating chemotherapy-induced neurodegeneration DOI
Pankaj Pal, Monika Sharma, Sukesh Kumar Gupta

et al.

Biochemical and Biophysical Research Communications, Journal Year: 2024, Volume and Issue: 734, P. 150778 - 150778

Published: Oct. 1, 2024

Language: Английский

Citations

0
Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons
Xue Zou, David R. Brigstock

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2848 - 2848

Published: Dec. 14, 2024

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of triglycerides within hepatocytes, which can progress to more severe conditions, such as metabolic steatohepatitis (MASH), may include progressive fibrosis, leading cirrhosis, cancer, and death. This goal this review highlight recent research showing potential mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in reducing key pathogenic pathways MASLD or MASH. Methods: Relevant published studies were identified using PubMed with one following search terms: MASLD, MASH, NAFLD, NASH, exosome, vesicle (EV), therapy, and/or cells (MSC). The primary literature subsequently downloaded summarized. Results: Using vitro vivo models, MSC-EVs have been found counteract oxidative stress, a significant contributor injury suppress progression, including steatosis, inflammation, and, few instances, fibrosis. Some these outcomes attributed specific EV cargo components microRNAs proteins. Thus, enriched types molecules improved therapeutic efficacy for MASLD/MASH represent novel approach potentially halt reverse process. Conclusions: are attractive agents treating MASLD/MASH. Further necessary validate clinical applicability human MASH patients, focusing on optimizing delivery strategies identifying that targeted components.

Language: Английский

Citations

0